Hemophilia Treatment Market Research Reports, Analysis, Market Trends and Forecast

Overview

Hemophilia Treatment Market Introduction

The global hemophilia treatment market is forecasted to value over US$ 15 billion by the end of 2026 and grow at a CAGR of over 5% during the forecast period of 2019-2026.

Hemophilia is a hereditary genetic disorder where the body’s coagulation control or blood clotting ability is impaired. Essentially, due to lack of sufficient amount of blood-clotting proteins or clotting factors, your blood is unable to clot normally. The inherited hemophilia is generally found in men as it is passed to them by the X chromosome of their mother. Hemophilia occurs in three forms – hemophilia A, hemophilia B and hemophilia C. The most commonly formed is the hemophilia A which is due to lack of factor VIII. Hemophilia B occurs due to lack of factor IX and hemophilia C occurs due to lack of factor XI. A limited presence of these disorders will be a driving force for research and development which will in turn boost the market growth during the forecast period. Along with that, government initiatives that are supporting the market and aggressive campaigning for the same will increase the requirement of diagnostics aids.

Hemophilia Treatment Market Overview

According to NORD, hemophilia A affects 1 in 5,000 males born in the US. It is the second most common inherited clotting disorder and it is estimated that 75% of global hemophilia patient has no proper access to treatment. Presently, there is no cure for hemophilia A and treatments are majorly concentrated on the management of the disease. It is assumed that 60% of the patient population develops a severe form of hemophilia. They are huge demand for effective management of hemophilia due to highly unmet medical need and it offers monopolistic opportunities for manufacture. Further, supportive regulatory conditions like research incentives & fast approvals boosted the research activities in hemophilia A treatment area. Further, technological advancements led to the integration of gene therapies in the treatment of hemophilia A and created opportunities for innovators.

North America market is expected to witness high market share in the global market due to supportive regulatory policies and high awareness. It is followed by the European region and it accounts a significant share in the global market. Asia-Pacific regions are expected to witness a high market growth rate during the forecast period due to increasing awareness and changing healthcare policies. Latin America and Rest of the world market are expected to account a small fraction of market share due to lack of awareness.

Hemophilia A Treatment market players include Spark Therapeutics, Novo Nordisk, Pfizer Inc, Bayer AG, CSL Behring, Baxter, Kedrion SPA, and others

Hemophilia Treatment Market

Hemophilia Treatment Market Segmentation

By Therapy Type

+ Replacement Therapy

+ Management Therapy

By End User

+ Hospital

+ Clinic

+ Others

By Region

+ North America

+ Latin America

+ Europe

+ Asia Pacific

+ Rest of the World

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the global Hemophilia Treatment Market by Therapy Type, by End-User, by Region

• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies